ViiV
Generics continue to erode GSK sales
May 6, 2015Sales and Marketing GSK, HIV, Novartis, Q1, ViiV, Witty, hampton, respiratory
GlaxoSmithKline’s pharma sales continued to slide in the first quarter of 2015, but ViiV healthcare and the portfolios acquired from …
GSK blames respiratory woes as sales drop
February 5, 2015Sales and Marketing Advair, GSK, GlaxoSmithKline, HIV, ViiV, Witty, anoro ellipta, breo, lovaza, q4, sales
GlaxoSmithKline’s respiratory business has been flagged as the key factor in the firm’s fourth quarter financial misfortunes, as its total …
GSK mulls $27 billion ViiV sell-off
October 23, 2014Medical Communications, Sales and Marketing AIDS, Advair, GSK, HIV, Pfizer, Q3, Shionogi, Tivicay, ViiV
After a difficult few years and another poor quarter, GlaxoSmithKline has announced that it is looking to float its fast-growing …
Pharma’s reputation ‘getting worse’
February 17, 2014Medical Communications, Sales and Marketing GSK, Gilead, Pfizer, ViiV, patientview, pharma, reputation
The pharma industry’s reputation is getting worse – at least, in the eyes of 800 patient groups – according to …
HIV pill Tivicay gains FDA approval
August 14, 2013Sales and Marketing FDA, GSK, Tivicay, ViiV
ViiV and partner GlaxoSmithKline’s new HIV drug Tivicay has been shown the FDA’s green light for distribution in the US. …
ViiV HIV drug boost
February 18, 2013Sales and Marketing Dolutegravir, GSK, HIV, ViiV
ViiV Healthcare has received a boost with the news that the FDA is to give a priority review to its …
Shionogi and ViiV strike new HIV deal
October 30, 2012Research and Development, Sales and Marketing Atripla, Dolutegravir, HIV, Shionogi, ViiV
HIV specialist firm ViiV Healthcare has announced a new deal with Japan’s Shionogi on a promising new treatment. ViiV Healthcare …
ViiV Healthcare appoints Just:: Health PR
April 12, 2012Medical Communications, Sales and Marketing HIV/AIDS, Just::, PR, ViiV
ViiV Healthcare has appointed Just:: Health PR to work on an integrated political and public relations initiative that will engage …
David Redfern appointed ViiV chairman
February 28, 2011Research and Development, Sales and Marketing David Redfern, GSK, GlaxoSmithKline, Pfizer, ViiV, ViiV Healthcare, appointment, research and development, sales and marketing
David Redfern has been appointed as chairman of ViiV Healthcare, the joint GlaxoSmithKline-Pfizer venture focused on HIV.
Digital Pharma: Byte-sized roundup
January 8, 2010Medical Communications Diabetes UK, NICE, Shire, ViiV, digital pharma, doctors.net, iphone
Includes online petition against NICE decision, Shire brings ADHD to Twitter, ViiV joins Twitter, Doctors.net.uk launches iPhone app and Diabetes …
GlaxoSmithKline-Pfizer launch HIV joint venture
November 4, 2009Research and Development, Sales and Marketing GSK, HIV, Pfizer, ViiV
GlaxoSmithKline and Pfizer have launched a specialist HIV company with access to ten medicines developed by the two manufacturers.ViiV Healthcare, …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
